Sartorius Stedim Biotech (SSB) is a leading global partner for the biopharmaceutical industry. The company focuses on single-use technologies and provides a comprehensive portfolio of products and services for biopharmaceutical development, quality assurance, and production processes. This includes cell cultivation, fermentation, filtration, purification, fluid management, and laboratory essentials. SSB empowers its customers worldwide to develop and manufacture biotech medications and vaccines safely, efficiently, and economically.
The Aubagne headquarters serves as the central hub for global operations, strategic decision-making, specific R&D activities (especially in polymers and single-use technologies), manufacturing of key product lines like single-use bags, and administrative functions for Sartorius Stedim Biotech.
The Aubagne campus is a major site for the innovation, development, and manufacturing of single-use bioprocessing technologies. It features advanced manufacturing facilities, R&D laboratories, and modern office spaces designed to foster collaboration and innovation.
The work culture at the Aubagne HQ is characterized by a strong focus on innovation, quality, and customer solutions within the dynamic biopharmaceutical sector. It combines French work-life considerations with an international, science-driven, and collaborative environment.
Aubagne is strategically important as the birthplace of Stedim's pioneering single-use bag technology and remains a critical center for Sartorius Stedim Biotech's leadership in single-use bioprocessing solutions, anchoring its strong presence in Europe and globally.
Sartorius Stedim Biotech supports the global biopharmaceutical industry with a worldwide network of approximately 60 manufacturing sites, R&D centers, sales offices, and service hubs. Key functions supported globally include product development, manufacturing of single-use and reusable bioprocessing equipment, quality assurance, supply chain management, technical support, application services, and sales & marketing, ensuring close proximity and tailored solutions for customers across all major biopharma markets in the Americas, Europe, Asia-Pacific, and Middle East & Africa.
Z.I. Les Paluds, Avenue de Jouques, CS 91051
Aubagne
Provence-Alpes-Côte d'Azur
France
Address: Otto-Brenner-Strasse 20, 37079 Goettingen, Germany
Serves as a central European hub and global R&D center, driving innovation across various product lines and supporting operations across Europe, Middle East, and Africa (EMEA) and globally.
Address: 5 Orville Dr, Bohemia, NY 11716, USA
Acts as a major operational center for the Americas, facilitating customer engagement, product delivery, and technical support for biotech and pharmaceutical clients in the region.
Address: Building 10, Lane 508, Chuan Qiao Road, Pudong, Shanghai, China
Supports regional customers with localized solutions and expertise, contributing to Sartorius's growth and presence in the Asian market.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Sartorius Stedim Biotech' leadership includes:
Sartorius Stedim Biotech has been backed by several prominent investors over the years, including:
The primary executive change at Sartorius Stedim Biotech in the last 12 months involved the finance leadership, with the appointment of a new Chief Financial Officer for Sartorius Stedim Biotech S.A.
Discover the tools Sartorius Stedim Biotech uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Sartorius Stedim Biotech, as part of the Sartorius Group, primarily uses a standard email format. The most common and effective format is combining the employee's first name and last name, separated by a period, followed by '@sartorius.com'. Variations may exist but are less common.
firstname.lastname@sartorius.com
Format
john.doe@sartorius.com
Example
95%
Success rate
Sartorius Official Website / Business Wire • April 25, 2024
Sartorius Stedim Biotech reported its Q1 2024 financial performance, indicating a moderate start as anticipated due to ongoing industry-wide normalization after high pandemic-driven demand. The company confirmed its full-year forecast, citing strong order intake towards the end of the quarter....more
Sartorius Official Website / GlobeNewswire • February 2, 2024
Sartorius Stedim Biotech announced its 2023 full-year results, showcasing resilience with solid sales revenue and profitability despite significant inventory destocking by customers and a general normalization of demand in the bioprocess market. The company highlighted strategic investments for future growth....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Sartorius Stedim Biotech, are just a search away.